ब्लिस जीव्हीएस फार्मा लिमिटेड

Corporate Identity Number (CIN): L24230MH1984PLC034771

नोंदणीकृत कार्यालय: १०२, हाईड पार्क, साकी विहार रोड, साकीनाका रोड, अंधेरी (पूर्व), मुंबई – ४०० ०७२

दूरध्वनी क्र: ०२२-४२१६०००० **फॅक्स:** ०२२-२८५६३९३० **वेबसाईट:** www.blissgvs.com **इमेल:** info@blissgvs.com/cs@blissgvs.com

सूचना

(कंपनीच्या ईक्विटी समभागधारकांनी लक्ष द्यावे यासाठी)
ईक्विटी समभागांचे आणि दावा न केलेले लाभांश
यांचे इनव्हेस्टर एज्युकेशन अँड प्रोटेक्शन फंड खात्यामध्ये हस्तांतरण

याद्वारे सूचना दिली जाते की कंपनी कायदा २०१३ च्या कलम १२४(६) च्या तरतूदी सहवाचित इनव्हेस्टर एज्युकेशन अँड प्रोटेक्शन फंड ऑथोरिटी (अकाऊंटींग, लेखापरीक्षण, हस्तांतरण आणि परतावा) नियम, २०१६ त्यानंतर वेळोवेळी सुधारणा केल्यानुसार (नियम), कंपनीचे ईक्विटी समभाग ज्यांच्या लाभांश रकमा सात वर्षांपासून किंवा त्याहून अधिक काळ विनादावा आहेत, त्या इनव्हेस्टर एज्युकेशन अँड प्रोटेक्शन फंड खात्यामध्ये हस्तांतरित करणे आवश्यक आहे (आयईपीएफ).

कंपनीने संबंधित समभागधारकांना ज्यांचे समभाग वरील नियमांप्रमाणे योग्य ती कृती करण्यासाठी आयईपीएफमध्ये हस्तांतरित करावयाचे आहेत त्यांच्याशी वैयक्तिक संपर्क पत्रव्यवहार केलेला आहे आणि अशा समभागांचे सर्व तपशील कंपनीच्या वेबसाईटवर www.blissgvs.com वर उपलब्ध करून देण्यात आलेले आहेत. संबंधित समभागधारकांनी सदर वेब लिंकवर जाऊन त्यांच्या कडे असलेल्या लाभांशाचे आणि त्या अनुषंगाने हस्तांतरित करण्यास पात्र समभागांचे तपशील तपासावेत.

समभागधारकांना, आयईपीएफमध्ये हस्तांतरण होण्याआधी २०१६-२०१७ या आर्थिक वर्षामध्ये आणि त्यानंतर जाहीर केलेल्या अंतिम लाभांशाचा दावा करण्याची विनंती केली जाते.

प्रत्यक्ष स्वरूपात समभाग असणारे संबंधित समभागधारक आणि ज्यांचे समभाग आयईपीएफमध्ये हस्तांतरित करण्यास पात्र आहेत त्यांनी नोंद घ्यावी की, नियमांच्या आवश्यकतेनुसार, मूळप्रत समभागधारकांकडे असल्याने आयईपीएफमध्ये हस्तांतरण करण्यासाठी कंपनी शेअर सर्टीफिकेट(स) ची नक्कलप्रत जारी करेल आणि अशा परिस्थितीत कंपनी डिपॉझिटरींना कॉर्पोरेट कृतीच्या माध्यमातून शेअर सर्टीफिकेट्सच्या नक्कलप्रती डिमॅट स्वरूपात बदलण्याबाबत आणि आयईपीएफ ऑथॉरीटीच्या नावे हस्तांतरित करण्याबाबत कळवेल. मूळ शेअर सर्टीफिकेट जे मूळ समभागधारकाच्या नावे नोंदणीकृत आहे ते आपोआप रद्द ठरवले जाईल आणि वाटाघाटी न करण्यायोग्य समजले जाईल. डिमटेरियलाईज्ड स्वरूपात समभाग असणाऱ्या संबंधित समभागधारकांनी नोंद घ्यावी की कंपनी डिपॉझिटरींना कॉर्पोरेट कृतीद्वारे समभाग आयईपीएफच्या डिमॅट अकाऊंटच्या नावे हस्तांतरित करण्याबद्दल कळवतील. ज्या समभागांच्याबाबतीत कोर्ट/ट्रायब्युनल यांचा कोणत्याही स्वरूपाचे हस्तांतरण रोखण्याबद्दल विशिष्ट आदेश असेल किंवा डिपॉझिटरीज कायदा, १९९६ द्वारे समभागांबाबत काही गृहितके/प्रतिज्ञा असतील तर असे समभाग कंपनी हस्तांतरित करणार नाही.

समभागधारक, जर प्रत्यक्ष स्वरूपात समभाग असतील तर त्यांच्या दावा न केलेल्या लाभांशावर कंपनी/रजिस्ट्रार आणि कंपनीचे ट्रान्सफर एजंट लिंक इनटाइम इंडिया प्रायव्हेट लिमिटेड यांना कळवु शकतात सोबत इन्व्हेस्टर सर्व्हिस रिक्वेस्ट फॉर्म आयएसआर-१, फॉर्म आयएसआर-२, फॉर्म क्र. एसएच १३ (वारसा अर्ज) आणि फॉर्म आयएसआर-३ (वारस न निवडणे) हे त्यातील सूचनांनुसार योग्यरित्या भरून सोबत आधार दस्तावेज जोडून पाठवावेत आणि जर समभाग डिमॅट स्वरूपात असतील तर मूळ रद्द केलेला धनादेश त्यावर खातेदाराचे नाव किंवा अपडेट केलेल्या खात्याच्या तपशीलासह क्लायंट मास्टर लिस्टची स्व-साक्षांकित प्रत जोडावी. कृपया नोंद घ्या लाभांशासाठी दावा करण्याची अखेरची तारीख नोव्हेंबर ०२, २०२४ रोजी किंवा त्यापूर्वी आहे. जर कंपनीला संबंधित समभागधारकांकडून काहीही माहिती न मिळाल्यास नियमांचे पालन करण्याच्या उद्देशाने कंपनी २०१६-२०१७ या आर्थिक वर्षाचा अंतिम लाभांश आयईपीएफ ऑथॉरिटीला हस्तांतरित करेल आणि तसेच संबंधित समभाग ज्यांवर ही लाभांश रक्कम विना दावा सात वर्षे पडून आहे ते समभागही पुढील कोणतीही सूचना न देता हस्तांतरित केले जातील.

संबंधित भागधारकांना यापुढे सूचित केले जाते की आयईपीएफ मध्ये समभाग हस्तांतरित केल्यानंतर, कंपनीतील तुमच्या शेअरहोल्डिंगमधून उद्भवणारे कोणतेही कॉर्पोरेट लाभ देखील आयईपीएफ ऑथॉरिटीला हस्तांतरित केले जातील.

कृपया नोंद घ्या की कंपनीविरूद्ध आयईपीएफ ऑथॉरीटीला हस्तांतरित केलेले समभाग आणि विना दावा लाभांश रक्कम याबाबतचा कोणताही दावा असणार नाही. समभागधारक लाभांश रक्कम आणि हस्तांतरित केलेले संबंधित समभाग तसेच त्यावरील सर्व लाभांसह जर काही असल्यास याबाबतचा दावा नियमांमध्ये नमूद केलेल्या विहित प्रक्रियेचे पालन करून आईपीएफ ऑथॉरीटीकडे करू शकतात.

वरील बाबतच्या कोणत्याही शंकांसाठी, समभागधारकांना कंपनीचे रजिस्ट्रार आणि शेअर ट्रान्सफर एजंट्स लिंक इनटाइम इंडिया प्रायव्हेट लिमिटेड, सी-१०१, २४७ पार्क, पहिला मजला, एलबीएस रोड, विक्रोळी (पश्चिम), मुंबई – ४०० ०८३, दूरध्वनी: ०२२-२८२०७२०३-०५ / ४९१८ ६१७८-७९ ईमेल: rnt.helpdesk@linkintime.co.in.

ब्लिस जीव्हीएस फार्मा लिमिटेड करिता
स्वाक्षरी
गगन शर्मा
व्यवस्थापकीय संचालक

ठिकाण : मुंबई
तारीख : ऑगस्ट ०२, २०२४

पिरामल कॅपिटल अँण्ड हाऊसिंग फायनान्स लि. (पीसीएचएफएल)

सीआयएन: एल६५९१०एमएच१९८४पीएलसी०३२६३९
नोंदणीकृत कार्यालय : युनिट क्र. ६०१, ६वा मजला, पिरामल अमिती बिल्डिंग, पिरामल अगस्त्या कॉर्पोरेट पार्क, कमानी जंक्शन, फायर स्टेशन समोर, एलबीएस मार्ग, कुर्ला (पश्चिम), मुंबई-४०००७० दू +९१ २२ ३८०२ ४०००

शाखा कार्यालय : धीरज बाग, इमारत ए तळ अधिक १ ला मजला, एक्सिस बँकेच्या बाजूला, मोनालिसा इमारत समोर, आग्रा रोड, हरि निवास सर्कल, नौपाडा, ठाणे (पश्चिम) ४००६०२, महाराष्ट्र.
संपर्क व्यक्ती: १. क्रिष्णा मिश्रा- ९०८२६२६५२२, २. श्री. विकास बनकर - ९९८७७५७५८०

सांकेतिक कब्जावर ई-लिलाव नवीन विक्री सूचना, ई-लिलाव तारीख: २०.०८.२०२४, स. ११.०० ते दु. २.००

कर्ज कोड/ शाखा/ कर्जदार/ सह-कर्जदार/ हमीदार	मागणी सूचनेची तारीख व रक्कम	मिळकत पत्ता अंतिम	राखीव किंमत	इसारा अनामत रक्कम (इअर) (रा. कि.च्या १०%)	थकबाकी रक्कम (०६.०६.२०२४)
(कर्ज कोड क्र. ०००००५२५१)/ (ठाणे शाखा) १. श्री. बालाजी असोसिएट्स् (कर्जदार/गहाणवटदार) २. श्री. अनिल कुरसिजा (एक मालकी हक्क संस्था)	१८-१०-२०१६ रु. १५,७६,२८,२९३/- (रुपये पंधरा कोटी शहात्तर लाख अठ्ठावीस हजार दोनशे त्र्याण्णव आणि शून्य पैसे मात्र)	ठाण्याच्या नोंदणी जिल्हा आणि उप जिल्ह्यात गाव ओवळे, तालुका आणि जिल्हा ठाणे येथे स्थित, असलेले, वसलेले सर्व्हे क्र. २३/४ (जुना क्र. १४१/४), २३/५ (जुना क्र. १४१/५) आणि २३/७ (जुना क्र. १४१/७) एकूण मोजमापित ५,६३० चौ. मी. किंवा आसपास सह त्यावरील वर्तमान आणि भविष्यातील बांधकाम आणि ''ट्रिनीटी हाईट्स्'' नामित प्रकल्पामधील त्यास जोडलेली जमीन सह सुविधाधिकार, जोडलेली सुविधा, वेणे, जाणे, पदपथ, संपर्क आणि त्यास जोडलेले काही असल्यास आणि इतर अनुषंगिक आणि जोडलेले हक्क आणि त्यावरील सर्व वर्तमान आणि भविष्यातील बांधकाम चे ते सर्व भाग आणि विभाग. परिशिष्ट- ॥ गाव ओवळे, घोडबंदर रोड लगत, ठाणे पश्चिमचा सर्व्हे क्र. २३/४/५/७ धारक जमीनीचा प्लॉट मोजमापित सुमारे ५,६३० चौ. मी. चे ते सर्व भाग आणि विभाग सह त्यावरील वर्तमान आणि भविष्यातील न विकलेले बांधकाम आणि पुढील बाबी समाविष्टीत परंतु त्या पर्यंत मर्यादित नसलेले नोंदणीकृत गहाणाच्या मार्गे अनन्य प्रभार.	रु. १५,२१,००,०००/- (रुपये पंधरा कोटी एकवीस लाख आणि शून्य पैसे मात्र)	रु. १,५२,१०,०००/- (रुपये एक कोटी बावन्न लाख दहा हजार आणि शून्य पैसे मात्र)	रु. ६२,१४,९१,७४६/- (रुपये बासष्ट कोटी चौदा लाख एक्याण्णव हजार सातशे सेहेचाळीस आणि शून्य पैसे मात्र)

एकल मालमत्तेच्या वैयक्तीक बोलीपेक्षा संपूर्ण बिल्डिंगसाठी बोली विचारात घेण्यात येईल.
विक्री ''जे आहे जेथे आहे'' आणि ''जे काही आहे तेथे आहे'' तत्वावर होईल.

ई-लिलावाची तारीख : २०.०८.२०२४, रोजी स. ११.०० ते दु. २.०० (प्रत्येक ५ मिनिटांच्या अमर्याद विस्तारासह),
बोली सादर करण्याची अंतिम तारीख : १९.०८.२०२४, सं. ४.०० पूर्वी.

विक्रीच्या तपशिलवार अटी आणि शर्तींकरीता कृपया **www.piramalfinance.com/e-Auction.html** मध्ये पुरविलेल्या लिंकचा संदर्भ घ्यावा किंवा **piramal.auction@piramal.com** वर आम्हाला ईमेल करावा.

कर्जदार/हमीदार/गहाणवटदार यांना सरफैसी ॲक्ट अंतर्गत वैधानिक १५ दिवसांची विक्री सूचना

वरील नमुद कर्जदार/हमीदार यांना लिलावाच्या तारखेपूर्वी तारखेपर्यंत उपार्जित व्याजासह संपूर्ण कलम १३(२) सूचनेमध्ये नमूद केल्यानुसार रक्कम चुकती करण्यासाठी याद्वारे सूचना देण्यात येत आहे, कसूर केल्यास मिळकतीचा लिलाव/विक्री करण्यात येईल आणि उर्वरित थकबाकी काही असल्यास कर्जदार/हमीदार यांच्याकडुन व्याज आणि खर्चासह वसुल करण्यात येईल.

दिनांक : ०२-०८-२०२४ **सही/- (प्राधिकृत अधिकारी)**
ठिकाण: ठाणे **पिरामल कॅपिटल अँण्ड हाऊसिंग फायनान्स लिमिटेड**

GARWARE SYNTHETICS LIMITED

Registered Address: Manish Textile Industrial Premises, Opp. Golden Chemical, Penkar Pada, Mira Road-401104
CIN: L99999MH1969PLC014371

Extract of the Standalone un-audited Financial Results for the Quarter ended 30th June, 2024.

Rs. In lacs

Sr. No.	Particulars	Quarter Ended			Year Ended
		30/06/2024 Unaudited	31/03/2024 Audited	30/06/2023 Unaudited	31/03/2024 Audited
1	Total Income	266.67	262.19	289.20	1071.92
2	Profit/(loss) before tax, exceptional items and extraordinary items	-11.97	-28.42	3.59	-41.92
3	Profit/(loss) before tax but after extra ordinary activities and exceptional items)	7.03	-0.92	3.59	-41.92
4	Net Profit/(loss) from ordinary activities after tax (9-10)	7.03	14.34	-3.02	-14.42
5	Net Profit/(loss) for the period (11+/-14)	7.03	14.34	-3.02	-4.77
6	Total Comprehensive Income for the period [comprising of Profit and Loss for the period (after tax) and other Comprehensive Income (After Tax)]	7.03	7.80	-3.02	-11.31
7	Paid- up Equity Share Capital (Face value shall be indicated)	580.89	580.89	580.89	580.89
8	Reserves Excluding (Revaluation Reserves) as shown in the Audited Balance sheet of previous year	-	-	-	261.88
9	i). Earnings per share (after extra ordinary items)				
	a. Basic	0.12	0.25	-0.05	-0.08
	b. Diluted	0.12	0.25	-0.05	-0.08

Notes:
a) The above is an extract of the detailed format of Quarter ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015.
b) The full format of the Quarter ended un-audited Financial Results is available on the websites of the Stock Exchange (www.bseindia.com).
c) Exceptional or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with IND-AS Rules / AS Rules, whichever is applicable.

For Garware Synthetics Limited
Sd/-
Sunder K. Moolya
Chairman & Whole Time Director
DIN: 02926064

Date: 01.08.2024
Place: Thane

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

Initial Public Offer of equity shares on the main board of BSE Limited (**"BSE"**) and National Stock Exchange of India Limited (**"NSE"**, and together with BSE, the **"Stock Exchanges"**) in compliance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (**"SEBI ICDR Regulations"**).

PUBLIC ANNOUNCEMENT

(Please scan the QR Code to view the DRHP)

Rubicon® RESEARCH
INNOVATION | QUALITY | CARE

RUBICON RESEARCH LIMITED

Our Company was incorporated on May 6, 1999, as a private limited company under the Companies Act, 1956, under the name 'Rubicon Consultants Private Limited', pursuant to a certificate of incorporation issued by the Registrar of Companies, Maharashtra at Mumbai ("**RoC**"). Subsequently, pursuant to a resolution passed by our Board and by our Shareholders on May 6, 2002 and June 15, 2002, respectively, the name of our Company was changed from 'Rubicon Consultants Private Limited' to 'Rubicon Research Private Limited' as we had set-up a pharma research laboratory, entered into contracts with customers from the pharma industry and was in the process of making applications to secretary, Department of Scientific and Industrial Research, Ministry of Science and Technology for carrying on scientific research development in our laboratories, consequent to which a fresh certificate of incorporation was issued by the RoC dated September 2, 2002 under the Companies Act, 1956. Furthermore, our Company's status was converted from a private limited company to a public limited company pursuant to a resolution passed by our Board and by our Shareholders on April 11, 2024 and May 13, 2024, respectively, the name of our Company was changed from 'Rubicon Research Private Limited' to 'Rubicon Research Limited' under Companies Act, 2013. A fresh certificate of incorporation dated July 23, 2024 was issued by the registrar of companies, central processing centre, Manesar, Haryana consequent to our Company's conversion into a public limited company. For details of change in the registered office of our Company, see *"History and Certain Corporate Matters - Changes in our registered office"* on page 255 of the draft red herring prospectus dated July 31, 2024 (**"DRHP"**).

Registered and Corporate Office: MedOne House, B-75, Road No. 33, Wagle Estate, Thane West - 400 604, Maharashtra, India
Contact Person: Deepashree Tanksale, Company Secretary and Compliance Officer; **Telephone:** 022 61414000, **Email:** investors@rubicon.co.in,
Website: www.rubicon.co.in, **Corporate Identity Number:** U73100MH1999PLC119744;

OUR PROMOTERS: GENERAL ATLANTIC SINGAPORE RR PTE. LTD., PRATIBHA PILGAONKAR, SUDHIR DHIRENDRA PILGAONKAR, PARAG SUGANCHAND SANCHETI, SURABHI PARAG SANCHETI, AND SUMANT SUDHIR PILGAONKAR

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH ("EQUITY SHARES") OF RUBICON RESEARCH LIMITED (FORMERLY KNOWN AS RUBICON RESEARCH PRIVATE LIMITED)(THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹10,850 MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹ 5,000 MILLION BY OUR COMPANY (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING UP TO ₹ 5,850 MILLION BY THE PROMOTER SELLING SHAREHOLDER, GENERAL ATLANTIC SINGAPORE RR PTE. LTD. (THE "OFFER FOR SALE").
THE OFFER PRICE IS [●] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMs, AND WILL BE ADVERTISED IN ALL EDITIONS OF THE ENGLISH NATIONAL DAILY NEWSPAPER [●], ALL EDITIONS OF THE HINDI NATIONAL DAILY NEWSPAPER [●] AND ALL EDITIONS OF THE MARATHI DAILY NEWSPAPER [●] (MARATHI BEING THE REGIONAL LANGUAGE OF MAHARASHTRA, WHERE OUR REGISTERED AND CORPORATE OFFICE IS LOCATED), EACH WITH WIDE CIRCULATION, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE", AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE "SEBI ICDR REGULATIONS").
THIS OFFER INCLUDES A RESERVATION OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹1 EACH, AGGREGATING UP TO ₹[●] MILLION (CONSTITUTING UP TO [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL), FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES ("EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". OUR COMPANY IN CONSULTATION WITH THE BRLMS, MAY OFFER A DISCOUNT OF UP TO ₹[●] TO THE OFFER PRICE (EQUIVALENT OF ₹[●] PER EQUITY SHARE) TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION ("EMPLOYEE DISCOUNT"). THE OFFER AND THE NET OFFER SHALL CONSTITUTE AT LEAST [●]% AND [●]%, RESPECTIVELY, OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.
OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER A PRE-IPO PLACEMENT, PRIOR TO FILING OF THE RED HERRING PROSPECTUS, SUBJECT TO RECEIPT OF APPROPRIATE APPROVALS. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SCRR. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE. PRIOR TO THE COMPLETION OF THE OFFER, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RHP AND THE PROSPECTUS.

In case of any revision to the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or unforeseen circumstances, our Company may, in consultation with the BRLMs, for reasons to be recorded in writing, extend the Bid / Offer Period for a minimum of one Working Day, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Member(s) and by intimation to the Designated Intermediaries and the Sponsor Bank(s), as applicable.

This is an Offer in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("**SCRR**"), read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process in terms of Regulation 6(2) of the SEBI ICDR Regulations, wherein in terms of Regulation 32(2) of the SEBI ICDR Regulations, not less than 75% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("**QIBs**", and such portion, the "**QIB Portion**") provided that our Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("**Anchor Investor Portion**"), of which at least one-third shall be reserved for allocation to domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB portion excluding the Anchor Investor Portion ("**Net QIB Portion**"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Net Offer shall be available for allocation to Non-Institutional Bidders out of which (a) one-third of such portion shall be reserved for applicants with application size of more than ₹200,000 and up to ₹1,000,000; and (b) two-third of such portion shall be reserved for applicants with application size of more than ₹1,000,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders and not more than 10% of the Net Offer shall be available for allocation to Retail Individual Bidders ("**RIBs**") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("**ASBA**") process by providing details of their respective bank accounts (including UPI ID for UPI Bidders using UPI Mechanism) (as defined hereinafter) in which the Bid amount will be blocked by the SCSBs or the Sponsor Banks, as applicable, to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Offer through the ASBA process. For details, see *"Offer Procedure"* on page 446 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP with the SEBI on August 1, 2024. Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI shall be made public for comments, if any, for a period of at least 21 days from the date of such filing by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, the website of the Company at www.rubicon.co.in and the websites of the Book Running Lead Managers ("**BRLMs**"), i.e. Axis Capital Limited, IIFL Securities Limited, JM Financial Limited and SBI Capital Markets Limited at www.axiscapital.co.in, www.iiflcap.com, www.jmfl.com and www.sbicaps.com, respectively. Our Company invites members of the public to give their comments on the DRHP filed with SEBI, with respect to disclosures made in the DRHP. The members of the public are requested to send a copy of their comments to SEBI and/or to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs on or before 5.00 p.m. on the 21st day from the aforesaid date of filing of the DRHP with SEBI.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the investors is invited to *"Risk Factors"* on page 28 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus (**"RHP"**) has been filed with the RoC and must be made solely on the basis of such RHP, as there may be material changes in the RHP from the DRHP. The Equity Shares, when offered through the RHP, are proposed to be listed on the Stock Exchanges.

For details of the share capital and capital structure of the Company, and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them, see '*Capital Structure*' beginning on page 101 of the DRHP. The liability of members of our Company is limited by Shares.

For details of the main objects of our Company as contained in the Memorandum of Association, see '*History and Certain Corporate Matters*' on page 255 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER
AXIS CAPITAL	IIFL SECURITIES	JM FINANCIAL	SBI CAPS (Complete Investment Banking Solutions)	LINKIntime
Axis Capital Limited 1st Floor, Axis House, C-2 Wadia International Center, Pandurang Budhkar Marg, Worli, Mumbai - 400 025, Maharashtra, India **Telephone:** +91 22 4325 2183 **E-mail:** rubicon.ipo@axiscap.in **Investor Grievance ID:** complaints@axiscap.in **Website:** www.axiscapital.co.in **Contact person:** Simran Gadh / Pratik Pednekar **SEBI Registration No.:** INM000012029	**IIFL Securities Limited** 24th Floor, One Lodha Place, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India **Tel:** + 91 22 4646 4728 **E-mail:** rubicon.ipo@iiflcap.com **Investor Grievance ID:** ig.ib@iiflcap.com **Website:** www.iiflcap.com **Contact person:** Aditya Raturi / Pawan Jain **SEBI Registration No.:** INM000010940	**JM Financial Limited** 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, Maharashtra, India **Telephone:** +91 22 6630 3030 **E-mail:** rrl.ipo@jmfl.com **Investor Grievance ID:** grievance.ibd@jmfl.com **Website:** www.jmfl.com **Contact person:** Prachee Dhuri **SEBI Registration No.:** INM000010361	**SBI Capital Markets Limited** 1501, 15th Floor, A & B Wing Parinee Crescenzo, BKC, Bandra (East), Mumbai - 400 051, Maharashtra, India **Telephone:** +91 22 4006 9807 **E-mail:** rubicon.ipo@sbicaps.com **Investor Grievance ID:** investor.relations@sbicaps.com **Website:** www.sbicaps.com **Contact person:** Vaibhav Shah **SEBI Registration No.:** INM000003531	**Link Intime India Private Limited** C-101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai - 400 083, Maharashtra, India **Tel:** +91 81081 14949 **E-mail:** rubicon.ipo@linkintime.co.in **Investor Grievance ID:** rubicon.ipo@linkintime.co.in **Website:** www.linkintime.co.in **Contact person:** Shanti Gopalkrishnan **SEBI Registration No.:** INR000004058

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For **RUBICON RESEARCH LIMITED**
On behalf of the Board of Directors
Sd/-
Deepashree Tanksale
Company Secretary and Compliance Officer

Place: Thane, Maharashtra
Date: August 1, 2024

RUBICON RESEARCH LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the DRHP with the SEBI on August 1, 2024. The DRHP shall be available on the website of SEBI at www.sebi.gov.in, on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.rubicon.co.in and the websites of the Book Running Lead Managers ("**BRLMs**"), i.e. Axis Capital Limited, IIFL Securities Limited, JM Financial Limited and SBI Capital Markets Limited at www.axiscapital.co.in, www.iiflcap.com, www.jmfl.com and www.sbicaps.com, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section entitled ***'Risk Factors'*** on page 28 of the DRHP. Potential investors should not rely on the DRHP filed with SEBI for making any investment decision.

This announcement is not an offer of securities for sale in the United States or elsewhere. This announcement has been prepared for publication in India only and is not for publication or distribution, directly or indirectly, in or into the United States. The Equity Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are only being offered and sold (a) within the United States solely to persons who are reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) in transactions exempt from the registration requirements of the U.S. Securities Act, and (b) outside the United States in "offshore transactions"as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur.

SECOND CORRIGENDUM TO THE DETAILED PUBLIC STATEMENT DATED NOVEMBER 19, 2018 AND THE FIRST CORRIGENDUM DATED APRIL 17, 2024 WITH RESPECT TO THE OPEN OFFER TO THE PUBLIC SHAREHOLDERS OF

FORTIS MALAR HOSPITALS LIMITED

HAVING ITS REGISTERED OFFICE AT FORTIS HOSPITAL, SECTOR-62, PHASE-VIII, MOHALI, PUNJAB – 160062, INDIA
TEL: +91 172 5096001 FAX: +91 172 5096002

OPEN OFFER FOR ACQUISITION OF UP TO 4,894,308 (FOUR MILLION, EIGHT HUNDRED AND NINETY FOUR THOUSAND, THREE HUNDRED AND EIGHT ONLY) FULLY PAID UP EQUITY SHARES OF FACE VALUE OF INR 10 (RUPEES TEN) EACH (**"EQUITY SHARES"**), REPRESENTING 26.00% (TWENTY SIX PERCENT) OF THE VOTING SHARE CAPITAL OF FORTIS MALAR HOSPITALS LIMITED (**"TARGET COMPANY"**) FROM THE PUBLIC SHA